AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15670545 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (various doses)
Number of subjects: 811
Study 15670545 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (various doses)
Number of subjects: 811
Study 15670545 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (various doses)
Number of subjects: 811
Study 15670545 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment with rosuvastatin, atorvastatin, simvastatin, and pravastatin
Number of subjects: 811
Study 14746860 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) at a dose of 80 mg/m(2) every 14 days for four courses, followed by delayed surgery and two more similar CDDP courses for SR-HB patients.
Number of subjects: 135
Study 14746860 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (CDDP) alternating every 14 days with carboplatin (CARBO), 500 mg/m(2), and doxorubicin (DOXO), 60 mg/m(2) for HR-HB patients.
Number of subjects: 135
Study 10693095 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine positioning
Number of subjects: 22
Study 10693095 — intervention group
Group type: COMPARATOR
Intervention: Prone positioning
Number of subjects: 22
Study 9092746 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycolic acid treatment
Number of subjects: 0
Study 9092746 — intervention group
Group type: EXPERIMENTAL
Intervention: Jessner's solution treatment
Number of subjects: 0
Study 9092746 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment effect
Number of subjects: 0
Study 9092746 — intervention group
Group type: EXPERIMENTAL
Intervention: Wood's light examination
Number of subjects: 0
Study 8250708 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine (300 mg bolus followed by 37.5 mg/h)
Number of subjects: 114
Study 8250708 — intervention group
Group type: COMPARATOR
Intervention: Sucralfate (1 g every 6 hours suspended in 20 mL of sterile water)
Number of subjects: 114
Study 3080867 — intervention group
Group type: EXPERIMENTAL
Intervention: Lipid-supplemented group
Number of subjects: 25
Study 3080867 — intervention group
Group type: COMPARATOR
Intervention: Lipid-restricted group
Number of subjects: 25
Study 3080867 — intervention group
Group type: COMPARATOR
Intervention: Initial plasma choline concentrations in malnourished patients
Number of subjects: 25
Study 31002812 — intervention group
Group type: EXPERIMENTAL
Intervention: VR combined real instrument training
Number of subjects: 31
Study 31002812 — intervention group
Group type: COMPARATOR
Intervention: Conventional occupational therapy
Number of subjects: 31
Study 29378718 — intervention group
Group type: EXPERIMENTAL
Intervention: Clofazimine (CLO)
Number of subjects: 49
Study 29378718 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 49
Study 26762204 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab (beva) + CCNU chemotherapy
Number of subjects: 0
Study 24635342 — intervention group
Group type: EXPERIMENTAL
Intervention: AEX+WL
Number of subjects: 77
Study 24635342 — intervention group
Group type: COMPARATOR
Intervention: WL
Number of subjects: 77
Study 22711898 — intervention group
Group type: EXPERIMENTAL
Intervention: Rizatriptan (5 mg for < 40 kg, 10 mg for ≥ 40 kg)
Number of subjects: 570
Study 22711898 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study 20035922 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspherical intraocular lens (Akreos Advanced Optic)
Number of subjects: 25
Study 20035922 — intervention group
Group type: COMPARATOR
Intervention: Spherical intraocular lens (Akreos Fit)
Number of subjects: 25
Study 18272093 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.05 mg/kg morphine then 0.025 mg/kg every 5 minutes (group A)
Number of subjects: 106
Study 18272093 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1 mg/kg morphine then 0.05 mg/kg every 5 minutes (group B)
Number of subjects: 106
Study 15755947 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 0
Study 15755947 — intervention group
Group type: COMPARATOR
Intervention: Full‐field digital mammography
Number of subjects: 0
Study 15755947 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer‐aided detection
Number of subjects: 0
Study 15755947 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical breast examination
Number of subjects: 0
Study 15755947 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast self‐examination
Number of subjects: 0
Study 15755947 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic resonance imaging (MRI)
Number of subjects: 0
Study 12778779 — intervention group
Group type: COMPARATOR
Intervention: Infusions taken directly from a warming box in the ambulance (Group A, n = 25)
Number of subjects: 50
Study 12778779 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusions taken from the warming box and packed in an insulation device (Group B, n = 25)
Number of subjects: 50
Study 9704787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal plasma interleukin‐6 concentrations > 11 pg/mL
Number of subjects: 157
Study 9704787 — intervention group
Group type: COMPARATOR
Intervention: Fetal plasma interleukin‐6 concentrations ≤ 11 pg/mL
Number of subjects: 157
Study 9704787 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall prevalence of severe neonatal morbidity among survivors
Number of subjects: 157
Study 9704787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal plasma interleukin‐6 concentrations
Number of subjects: 157
Study 9704787 — intervention group
Group type: EXPERIMENTAL
Intervention: Fetal plasma interleukin‐6 concentrations in subset of patients (73 fetuses delivered within 7 days of cordocentesis)
Number of subjects: 157
Study 7702028 — intervention group
Group type: EXPERIMENTAL
Intervention: Pasta meal
Number of subjects: 10
Study 7702028 — intervention group
Group type: EXPERIMENTAL
Intervention: Parboiled rice meal
Number of subjects: 10
Study 7702028 — intervention group
Group type: COMPARATOR
Intervention: High-GI meals (control)
Number of subjects: 10
Study 2674246 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal weight patient
Number of subjects: 100
Study 2674246 — intervention group
Group type: EXPERIMENTAL
Intervention: Obese patient
Number of subjects: 100
Study 2674246 — intervention group
Group type: COMPARATOR
Intervention: Male patient
Number of subjects: 100
Study 2674246 — intervention group
Group type: COMPARATOR
Intervention: Female patient
Number of subjects: 100
Study 67805 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized audiovisual patient education program about digoxin
Number of subjects: 0
Study 67805 — intervention group
Group type: COMPARATOR
Intervention: Traditionally-educated patients
Number of subjects: 0
Study 29513248 — intervention group
Group type: EXPERIMENTAL
Intervention: Endoscopic sclerotherapy with 3-day substitution therapy of deficient factors VIII or IX
Number of subjects: 22
Study 29513248 — intervention group
Group type: COMPARATOR
Intervention: Control group of 20 non‐hemophiliac patients with liver cirrhosis
Number of subjects: 22
Study 26918279 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-102 (35 mg/m²) administered in a single dose during pharmacokinetic phase and twice-daily doses in 28-day cycles during repeated administration phase.
Number of subjects: 9
Study 26918279 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-102 (twice-daily doses) during repeated administration phase.
Number of subjects: 9
Study 26918279 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-102 (postprandial administration).
Number of subjects: 9
Study 26918279 — intervention group
Group type: EXPERIMENTAL
Intervention: TAS-102.
Number of subjects: 9
Study 24886107 — intervention group
Group type: EXPERIMENTAL
Intervention: Whole-body vibration
Number of subjects: 300
Study 24886107 — intervention group
Group type: COMPARATOR
Intervention: Multicomponent Training
Number of subjects: 300
Study 22226329 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise training (8-week aerobic exercise program)
Number of subjects: 38
Study 22226329 — intervention group
Group type: COMPARATOR
Intervention: Control (standard medical care and follow-up)
Number of subjects: 38
Study 20381653 — intervention group
Group type: EXPERIMENTAL
Intervention: Medtronic AVE Interceptor Saphenous Vein Graft Filter System (EPD)
Number of subjects: 748
Study 20381653 — intervention group
Group type: COMPARATOR
Intervention: GuardWire or FilterWire EPD (Control)
Number of subjects: 748
Study 18760041 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 60
Study 18760041 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 60
Study 16463831 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (20 mmol over 10 min followed by an infusion of 4 mmol/h)
Number of subjects: 18
Study 16463831 — intervention group
Group type: COMPARATOR
Intervention: Intravenous saline (control)
Number of subjects: 18
Study 12431857 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute tryptophan depletion (ATD)
Number of subjects: 45
Study 12431857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 10398629 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast (10 mg tablet) once daily at bedtime for up to 12 weeks
Number of subjects: 226
Study 10398629 — intervention group
Group type: COMPARATOR
Intervention: Placebo once daily at bedtime for up to 12 weeks
Number of subjects: 226
Study 10398629 — intervention group
Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 226
Study 10398629 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 226
Study 7570431 — intervention group
Group type: EXPERIMENTAL
Intervention: Once weekly physiotherapy (group A) after initial twice weekly sessions for 3 months
Number of subjects: 36
Study 7570431 — intervention group
Group type: EXPERIMENTAL
Intervention: Once monthly physiotherapy (group B) after initial twice weekly sessions for 3 months
Number of subjects: 36
Study 7570431 — intervention group
Group type: COMPARATOR
Intervention: No rehabilitation (control group C)
Number of subjects: 36
Study 2112131 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% lidocaine inhalation
Number of subjects: 18
Study 2112131 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (placebo)
Number of subjects: 18
Study 378094 — intervention group
Group type: EXPERIMENTAL
Intervention: Inderectic (propranolol 80 mg and bendrofluazide 2.5 mg, given twice daily)
Number of subjects: 21
Study 378094 — intervention group
Group type: COMPARATOR
Intervention: Free combination of propranolol and bendrofluazide (given as separate tablets)
Number of subjects: 21
Study 378094 — intervention group
Group type: COMPARATOR
Intervention: Propranolol alone
Number of subjects: 21
Study 378094 — intervention group
Group type: COMPARATOR
Intervention: Bendrofluazide alone
Number of subjects: 21
Study 6840831 — intervention group
Group type: EXPERIMENTAL
Intervention: liver-solution with 45% branched chain amino acids
Number of subjects: 18
Study 6840831 — intervention group
Group type: COMPARATOR
Intervention: conventional solution with 10.5% branched chain amino acids
Number of subjects: 18
Study 29290078 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT target of 300 seconds
Number of subjects: 68
Study 29290078 — intervention group
Group type: COMPARATOR
Intervention: ACT target of 450 seconds
Number of subjects: 68
Study 29290078 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 68
Study 30591575 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily SMS quizzes
Number of subjects: 106
Study 30591575 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily SMS quizzes with daily readings and online CME courses
Number of subjects: 106
Study 30591575 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 106
Study 27465329 — intervention group
Group type: EXPERIMENTAL
Intervention: Bosentan
Number of subjects: 0
Study 27465329 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 24506265 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 ml 1% methylene blue and 16 ml 0.5% marcaine
Number of subjects: 67
Study 24506265 — intervention group
Group type: COMPARATOR
Intervention: 16 ml 0.5% marcaine and 4 ml saline (placebo)
Number of subjects: 67
Study 24506265 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 67
Study 21450562 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine Replacement Therapy (NRT)
Number of subjects: 481
Study 21450562 — intervention group
Group type: EXPERIMENTAL
Intervention: More intensive NRT at week 4
Number of subjects: 481
Study 19679221 — intervention group
Group type: EXPERIMENTAL
Intervention: Glucosamine
Number of subjects: 36
Study 19679221 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen
Number of subjects: 36
Study 19679221 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study 19679221 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (Glucosamine, Ibuprofen, Placebo)
Number of subjects: 36
Study 17927638 — intervention group
Group type: EXPERIMENTAL
Intervention: Innovative manual toothbrush
Number of subjects: 30
Study 17927638 — intervention group
Group type: COMPARATOR
Intervention: Traditional toothbrush
Number of subjects: 30
Study 17927638 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study 17927638 — intervention group
Group type: EXPERIMENTAL
Intervention: Test group
Number of subjects: 30
Study 15843221 — intervention group
Group type: EXPERIMENTAL
Intervention: 7-oxo-dehydroepiandrosterone (25 mg daily transdermally for 8 days)
Number of subjects: 21
Study 12079252 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral counseling plus cognitive‐behavioral mood management training (CBT)
Number of subjects: 51
Study 12079252 — intervention group
Group type: COMPARATOR
Intervention: Behavioral counseling (BC)
Number of subjects: 51
Study 9791752 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaccinated children (PRP-T vaccine)
Number of subjects: 102
Study 9791752 — intervention group
Group type: COMPARATOR
Intervention: Non-vaccinated children
Number of subjects: 102
Study 7881681 — intervention group
Group type: COMPARATOR
Intervention: Standard physical therapy (STD)
Number of subjects: 35
Study 7881681 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of standard therapy with exercise (EX)
Number of subjects: 35
Study 2757665 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 10 mg
Number of subjects: 12
Study 2757665 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 30 mg
Number of subjects: 12
Study 2757665 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 840117 — intervention group
Group type: EXPERIMENTAL
Intervention: Streptokinase
Number of subjects: 1463
Study 840117 — intervention group
Group type: COMPARATOR
Intervention: Control (no streptokinase)
Number of subjects: 1463
Study 31170712 — intervention group
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl (Bard) 20 mg once daily
Number of subjects: 2185
Study 31170712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2185
Study 27604584 — intervention group
Group type: EXPERIMENTAL
Intervention: Imageless navigation
Number of subjects: 135
Study 27604584 — intervention group
Group type: COMPARATOR
Intervention: Estimation by eye and palpation (control)
Number of subjects: 135
Study 27604584 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (navigated and control)
Number of subjects: 135
Study 26580249 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine at appearance of the fourth twitch of a 'train‐of‐four'
Number of subjects: 48
Study 26580249 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine at loss of fade to train‐of‐four
Number of subjects: 48
Study 26580249 — intervention group
Group type: EXPERIMENTAL
Intervention: Neostigmine at loss of fade to double‐burst stimulation
Number of subjects: 48
Study 26580249 — intervention group
Group type: COMPARATOR
Intervention: Comparison of recovery times
Number of subjects: 48
Study 23934045 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg parecoxib injected intravenously 30 min before surgery and every 12 h for 2 days
Number of subjects: 40
Study 23934045 — intervention group
Group type: COMPARATOR
Intervention: Incision-local block with 5 ml of 0.5% ropivacaine and 20 ml of physiological saline every 12 h for 2 days
Number of subjects: 40
Study 21114583 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined metformin and clomiphene citrate (CC)
Number of subjects: 282
Study 21114583 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic ovarian diathermy (LOD)
Number of subjects: 282
Study 20003788 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifemin 20 mg bid po for 12 weeks
Number of subjects: 180
Study 20003788 — intervention group
Group type: COMPARATOR
Intervention: Tibolone 2.5 mg qd po for 12 weeks
Number of subjects: 180
Study 16941068 — intervention group
Group type: EXPERIMENTAL
Intervention: Fosfomycin trometamol (single dose)
Number of subjects: 84
Study 16941068 — intervention group
Group type: COMPARATOR
Intervention: Cefuroxime axetyl (5-day regimen)
Number of subjects: 84
Study 15532067 — intervention group
Group type: EXPERIMENTAL
Intervention: Test bromazepam formulation (6 mg)
Number of subjects: 27
Study 15532067 — intervention group
Group type: COMPARATOR
Intervention: Reference bromazepam formulation (6 mg)
Number of subjects: 27
Study 11026946 — intervention group
Group type: EXPERIMENTAL
Intervention: Couple therapy
Number of subjects: 77
Study 11026946 — intervention group
Group type: COMPARATOR
Intervention: Antidepressant drugs
Number of subjects: 77
Study 8970891 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological intervention
Number of subjects: 958
Study 8970891 — intervention group
Group type: EXPERIMENTAL
Intervention: Social domain
Number of subjects: 958
Study 8970891 — intervention group
Group type: EXPERIMENTAL
Intervention: Biomedical domain
Number of subjects: 958
Study 8970891 — intervention group
Group type: EXPERIMENTAL
Intervention: Care domain
Number of subjects: 958
Study 8970891 — intervention group
Group type: EXPERIMENTAL
Intervention: General quality of life
Number of subjects: 958
Study 8970891 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression
Number of subjects: 958
Study 8970891 — intervention group
Group type: EXPERIMENTAL
Intervention: Health status
Number of subjects: 958
Study 1315212 — intervention group
Group type: EXPERIMENTAL
Intervention: WR-2721 (100 mg/enema to 450 mg/enema)
Number of subjects: 31
Study 1315212 — intervention group
Group type: COMPARATOR
Intervention: Control group (no WR-2721)
Number of subjects: 31
Study 3876591 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim/sulphamethoxazole treatment in achlorhydric and postgastrectomy patients
Number of subjects: 51
Study 3876591 — intervention group
Group type: COMPARATOR
Intervention: Hydrogen (H2) breath test
Number of subjects: 51
Study 3876591 — intervention group
Group type: COMPARATOR
Intervention: Standardized meal before H2 breath test
Number of subjects: 51
Study 3876591 — intervention group
Group type: COMPARATOR
Intervention: Correlation of total bacterial concentration in gastric juice
Number of subjects: 51
Study 30860407 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural Grass (NG)
Number of subjects: 9
Study 30860407 — intervention group
Group type: COMPARATOR
Intervention: Artificial Turf (AT)
Number of subjects: 9
Study 30519081 — intervention group
Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback (EMGBF) associated with isometric exercise
Number of subjects: 46
Study 30519081 — intervention group
Group type: COMPARATOR
Intervention: Isometric exercise without biofeedback
Number of subjects: 46
Study 27632841 — intervention group
Group type: EXPERIMENTAL
Intervention: Hip- or knee-muscle-strengthening rehabilitation
Number of subjects: 157
Study 23965225 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab (600 mg fixed-dose via single-use injection device)
Number of subjects: 248
Study 23965225 — intervention group
Group type: COMPARATOR
Intervention: Intravenous trastuzumab
Number of subjects: 248
Study 23965225 — intervention group
Group type: COMPARATOR
Intervention: No preference
Number of subjects: 248
Study 23965225 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous trastuzumab
Number of subjects: 248
Study 20194384 — intervention group
Group type: EXPERIMENTAL
Intervention: Pain‐Free (Parkell, Edgewood, N.Y.)
Number of subjects: 11
Study 20194384 — intervention group
Group type: EXPERIMENTAL
Intervention: Seal & Protect (Dentsply DeTrey, Konstanz, Germany)
Number of subjects: 11
Study 20194384 — intervention group
Group type: EXPERIMENTAL
Intervention: BisBlock (Bisco, Schaumburg, Ill.)
Number of subjects: 11
Study 18062976 — intervention group
Group type: EXPERIMENTAL
Intervention: STAEST (2g/day stanols)
Number of subjects: 19
Study 18062976 — intervention group
Group type: COMPARATOR
Intervention: Control (spread with no added stanols)
Number of subjects: 19
Study 16604824 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective brain cooling (SBC)
Number of subjects: 66
Study 16604824 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild systemic hypothermia (MSH)
Number of subjects: 66
Study 16604824 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 66
Study 14600686 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg of methylprednisolone sodium succinate (MP)
Number of subjects: 26
Study 14600686 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg/kg of methylprednisolone sodium succinate (MP)
Number of subjects: 26
Study 10912539 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily oral calcitriol (10 ng/kg per day)
Number of subjects: 59
Study 10912539 — intervention group
Group type: COMPARATOR
Intervention: Intermittent oral calcitriol (35 ng/kg given twice a week)
Number of subjects: 59
Study 10912539 — intervention group
Group type: COMPARATOR
Intervention: Both groups
Number of subjects: 59
Study 8982887 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 40
Study 8982887 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 5 micrograms/kg plus propofol
Number of subjects: 40
Study 8982887 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 10 micrograms/kg plus propofol
Number of subjects: 40
Study 8982887 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil 15 micrograms/kg plus propofol
Number of subjects: 40
Study 1550367 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotretinoin cream (0.05% for 3 months, then 0.1% for 6 months)
Number of subjects: 326
Study 1550367 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 326